How does Zenobia design it's shape diverse mixtures?
Why Screen as Mixtures? In many cases, it is much more efficient to screen as mixtures because it pares down the dataset to a manageable...
What is Crystallographic Screening and Why is it Making a Comeback?
What is Crystallographic Screening? Crystallographic screening is a method used to detect ligands that bind to a target protein. What...
Diversity Series, Part 1
PART 1: What is Chemical Diversity? This is the first in a three-part series discussing chemical diversity. In Part 1, we introduce the...
GoT Frags?
The "Guideline of Two" Over the past decade, a number of rules and calculated metrics have arisen in drug discovery. In particular, the...
Efficiency by Design
As fragment screening continues to grow in popularity and establish itself as an integral part of discovery research, the emergence of...
History of Zenobia Fragments
Zenobia Therapeutics was founded in 2008 by Drs Vicki Nienaber and Robert Meadows. Zenobia’s founders are pioneers in the field of...
Welcome to the Zenobia Fragments Blog!
Welcome to our new blog. Here, we will be sharing thoughts and opinions based upon our 20-30 years of experience in fragment screening...
